Subcutaneous Entyvio safe, effective for long-term maintenance of UC

The interim analysis of subcutaneous Entyvio demonstrates the treatment is safe and effective for long-term maintenance of ulcerative colitis, according to results presented at UEG Week.“These findings support the use of vedolizumab SC (vedolizumab, Takeda) at a dose of 108 mg every 2 weeks as a safe and effective alternative to IV administration for long-term maintenance treatment of patients with UC,” Séverine Vermeire, MD, PhD, from the University Hospital Leuven, Belgium.The VISIBLE open-label extension is an ongoing, multinational, multicenter phase 3 study of patientsRead More

Share on facebook
Share on twitter
Share on linkedin